Novavax's CIC Vaccine Rides the Wave of Technological Advancements

According to a report, Novavax's COVID-Influenza Combination (CIC) vaccine incorporates artificial intelligence (AI) in its development.

Inclusion of artificial intelligence (AI) in the development of Novavax's COVID-Influenza Combination (CIC) vaccine, reflects the wider adoption of AI in clinical trial design within the industry, according to a report on Thursday (18th May 2023).

Novavax recently announced results from a Phase II trial for its CIC vaccine. The data indicate that the vaccine candidate is safe, well tolerated, and exhibits a strong immune response comparable to that of both influenza vaccines Fluad and Fluzone HD, as well as Novavax's COVID vaccine NVX-CoV2373.

Artificial Intelligence in Healthcare - An Overview
Artificial intelligence (AI) in healthcare is the discipline using data intensive computer based solutions to improve patient care and outcome.

‘In line with a broader industry trend, Novavax's COVID-Influenza Combination (CIC) vaccine incorporates artificial intelligence (AI) in its development, as indicated by a report emphasizing the growing usage of AI in clinical trial design. ’

Groundbreaking Utilization of Artificial Intelligence

"Novavax's novel AI approach, which informed dose selection of the CIC vaccine candidate, is paying off. With Phase III trials set to begin later this year, Novavax has a good chance to bring the first combined COVID-influenza vaccine to market," said Stephanie Kurdach, Infectious Disease Analyst at GlobalData, a data and analytics company, in a statement.

The CIC vaccine has three components -- recombinant hemagglutinin (rHA) particles from four prominent influenza strains (H1N1, H3N2, B-Yamagata, and B-Victoria), recombinant spike (rS) nanoparticles from SARS-CoV-2, and Novavax's Matrix-M adjuvant.

A design of experiments (DoE) approach was used to predict appropriate dosing combinations to immunize patients and response surface modeling following immunization responses.

By simultaneously altering the rS and rHA doses within the model, it was possible to observe the antibody responses among each of the four influenza strains and SARS-CoV-2.

BioNTech's MRNA Vaccine Shows Promise in Combating Pancreatic Cancer
Promising results: BioNTech's mRNA vaccine shows safety and immune response in early-stage pancreatic cancer study, offering hope in fighting the disease.

Impact on Vaccine Innovation

The DoE software enabled more powerful fine-tuning of dose selection of the COVID and influenza antigens compared to conventional methods.

The CIC formulation determined by the DoE software implies up to a 50 percent reduction in total antigen content. Reduced antigen content in vaccines is equally as immunogenic, with increased tolerability for patients.

"The novel approach employed by Novavax is an exciting advance in vaccinology. Integrating AI methodologies into clinical trials has the potential to speed up existing processes, aid in decision-making, and reduce possible instances of human error," Kurdach said.

Novavax's trial design reflects a wider industry trend, as pharmaceutical companies are becoming highly active in utilizing AI technologies. It follows other companies such as AstraZeneca, Moderna, and Pfizer - - all of whom referenced AI methods during clinical trials for their COVID vaccines.

Why Should You Sleep Well Before Getting a Vaccine Shot?
Is lack of sleep bad for vaccine? Yes, sleeping less than 6 hours a night can affect your response to vaccination. So, sleep well to boost your vaccine response.

Harnessing the Power of AI

According to GlobalData, patent activity by pharmaceutical companies using AI reached an all-time high in 2022 -- accounting for 61 patent grants, 225 patent filings, and 299 patent publications.

Furthermore, there have been over 600 AI-related filings involving pharmaceutical companies in the last six months.

"AI algorithms are responsible for increasing the efficiency of mRNA sequence design and antigen detection. Without AI methodologies, there would not have been such a speedy vaccine response to the COVID pandemic," Kurdach said.

Source-IANS